First Country In Europe Launches Flutiform® (Fluticasone Propionate/Formoterol Fumarate), A New Combination Therapy For Asthma
Mundipharma has announced that flutiform® (fluticasone propionate/formoterol fumarate), a new combination therapy for the maintenance treatment of asthma, is now available for use in Germany. The German launch marks the first European country where flutiform can be prescribed for appropriate patients with asthma. Marketing authorisations have already been granted in Austria, Cyprus, Germany, Norway, The Netherlands, Slovakia, Sweden and the UK. The Netherlands and UK are due to launch imminently, with further national approvals and subsequent launches are expected across a number of European countries later in 2012 and 2013.
The combination of fluticasone propionate (fluticasone), an inhaled corticosteroid (ICS), and formoterol fumarate (formoterol), a long-acting β2-agonist (LABA) therapy is delivered via a single aerosol inhaler for the first time. The fluticasone/formoterolcombination is indicated for the regular treatment of asthma in patients aged 12 years and over (50/5µg and 125/5µg strengths: adults and adolescents; 250/10µg strength: adults only) whose symptoms are not adequately controlled on an ICS and an as-required inhaled short-acting β2-agonist (SABA), and in those patients who are already adequately controlled on both an ICS and LABA.[i]
“Asthma still represents an important clinical challenge despite currently available treatments,” said Prof. J. Christian Virchow, Head of Department of Pneumology/Intensive Care Medicine, University Hospital, Rostock, Germany. “The combination of fluticasone/formoterol brings together two well established asthma medications and has the potential to become a valuable new maintenance treatment option for asthma patients in clinical practice.”
Mundipharma International Corporation Limited is licensed by Jagotec AG, a SkyePharma Group company, as the authorised distributor of the fluticasone/formoterol combination for Europe and most other territories outside Japan and the Americas.
Understanding asthma patients in today’s world: European study
Simultaneously with providing a new maintenance treatment option for appropriate patients across Europe, Mundipharma is undertaking a pan-European survey of asthma patients. The aim of the research is to gain insights into perceptions and attitudes of patients towards asthma in the context of modern lifestyles to better understand the reasons behind the low levels of asthma control.[ii],[iii]
The results from this 10-country, large scale research of 8,000 asthma patients will be available later this year. Mundipharma is hoping the survey findings will add to the evidence around the reasons for suboptimal asthma control and inform asthma management strategies in the future.
[i] flutiform SmPC
[ii] GINA: GINA Report, Global Strategy for Asthma Management and Prevention. Website accessed August 2012: http://www.ginasthma.org/uploads/users/files/GINA_Report2011_May4.pdf
[iii] Haughney J, Price D, et al. Respir Med 2008;102:1681-93